Publications & News

WilmerHale Reps Emergent BioSolutions in $96M Acquisition of GlaxoSmithKline Anthrax Drug

July 24, 2017

Emergent BioSolutions, which offers specialized products to healthcare providers and governments to address medical needs and emerging health threats, announced it would acquire a drug for treating inhaled anthrax from pharmaceutical giant GlaxoSmithKline in an all-cash deal worth up to $96 million. The deal is expected to close by the end of the year.

The WilmerHale team representing Emergent BioSolutions was led by Jeffrey Hermanson and includes Belinda Juran, Sam Rothberg, Alex Civetta, Jasmine Haddad, Hartmut Schneider, Julie Hogan Rodgers and Bruce Manheim.

To learn more about the acquisition, read Emergent BioSolutions' press release.